Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Isaac Yeboah Addo, Frederick Dadzie, Sylvester Reuben Okeke, et al.
Archives of Public Health (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Rupsha Fraser, Aurelio Orta‐Resendiz, Alexander Mazein, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 4, pp. 255-267
Open Access | Times Cited: 31
Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines
Paolo Bellavite, Alessandra Ferraresi, Ciro Isidoro
Biomedicines (2023) Vol. 11, Iss. 2, pp. 451-451
Open Access | Times Cited: 29
Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh
Md. Ahsanul Haq, Anjan Kumar Roy, Razu Ahmed, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Cleo Anastassopoulou, Stefanos Ferous, Snežana Medić, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 566-566
Open Access | Times Cited: 6
Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study
Eric Kasongo Mukenge, Blaise Matondo Manzambi Sumbu, Aliocha Natuhoyila Nkodila, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients
K. L. Juliëtte Schmidt, Noël Dautzenberg, Peter M. Hoogerbrugge, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2562-2562
Open Access | Times Cited: 10
Association of Parsonage–Turner syndrome with COVID-19 infection and vaccination: a systematic review
Muhammad Zain Ameer, Ata Ul Haiy, Muhammad Hassan Bajwa, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 7
Open Access | Times Cited: 10
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding
Gemma E. Hartley, Holly A. Fryer, Paul A. Gill, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination
Alexa Keeshan, Yannick Galipeau, Aliisa Heiskanen, et al.
BMJ Open (2023) Vol. 13, Iss. 10, pp. e077714-e077714
Open Access | Times Cited: 7
Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
Camilo C. Roa, Mari Rose A de Los Reyes, Eric Plennevaux, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 9, pp. 1253-1262
Open Access | Times Cited: 6
Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2
Sebastian Alexander Müller, Sydney Paltra, Jakob Rehmann, et al.
iScience (2023) Vol. 26, Iss. 9, pp. 107554-107554
Open Access | Times Cited: 6
Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after mRNA but not adenovirus priming
Gemma E. Hartley, Holly A. Fryer, Paul A. Gill, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines
Akanksha Kale, Amitabh Gaur, Ipshita Menon, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 112, Iss. 5, pp. 1345-1350
Open Access | Times Cited: 5
A Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal Complications
Barbara Brogna, Elio Bignardi, A. Megliola, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2113-2113
Open Access | Times Cited: 5
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada
Shishi Wu, Yanhong Li, Stefan Baral, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0299304-e0299304
Open Access | Times Cited: 1
Deviation from the recommended schedule: optimal dosing interval for a two-dose vaccination programme
Zhen Wang, Gergely Röst, Seyed M. Moghadas
Royal Society Open Science (2024) Vol. 11, Iss. 7
Open Access | Times Cited: 1
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH)
Maxim Cherneha, Isabel Zydek, Peer Braß, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 785-785
Open Access | Times Cited: 1
Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico
María Elena Romero-Ibarguengoitia, Diego Rivera-Salinas, Riccardo Sarti, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 842-842
Open Access | Times Cited: 4
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial
Kenji Kuriyama, Kyoko Murakami, Taisei Masuda, et al.
Vaccine (2023) Vol. 41, Iss. 25, pp. 3763-3771
Open Access | Times Cited: 4
Factors Affecting SARS-CoV-2 IgG Production after Vaccination and/or Disease: A Large-Scale Seroprevalence Study
Tanja Karl, Anja Schuster, Lea Maria Stangassinger, et al.
Vaccines (2023) Vol. 11, Iss. 10, pp. 1615-1615
Open Access | Times Cited: 4
Associations of neuralgic amyotrophy with COVID‐19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database
Jee‐Eun Kim, Jin Myung Park, Young Gi Min, et al.
Muscle & Nerve (2022) Vol. 66, Iss. 6, pp. 766-770
Open Access | Times Cited: 7
Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study
Marlena Golec, Joanna Zembala-John, Martyna Fronczek, et al.
PLoS ONE (2023) Vol. 18, Iss. 6, pp. e0287128-e0287128
Open Access | Times Cited: 3
Retrospective Analysis of Vaccination Status and Predominant Viral Variants in Patients Hospitalized with COVID-19 in Reus, Spain
Simona Iftimie, Ana F. López‐Azcona, Maria José Lozano‐Olmo, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 886-886
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top